Menu
Back to Archived Journals » Reports in Parasitology » Volume 2
Synthesis of gold nanoparticles by the fungus Aspergillus niger and its efficacy against mosquito larvae
Authors Namita Soni N, Prakash S
Received 9 December 2011
Accepted for publication 9 February 2012
Published 11 June 2012 Volume 2012:2 Pages 1—7
DOI https://doi.org/10.2147/RIP.S29033
Review by Single anonymous peer review
Peer reviewer comments 3
Namita Soni, Soam Prakash
Environmental and Advanced Parasitology and Vector Control Biotechnology Laboratories, Department of Zoology, Faculty of Science, Dayalbagh Educational Institute, Dayalbagh, Agra, India
Background: The fungus Aspergillus niger has been selected for the synthesis of gold nanoparticles (AuNPs). The authors report the role of fungi in the synthesis of AuNPs. Additionally, the larvicidal efficacy of these AuNPs was tested using the larvae of three mosquito species: Anopheles stephensi, Culex quinquefasciatus, and Aedes aegypti.
Methods: The AuNPs were characterized through microplate reader analysis, X-ray diffraction, transmission electron microscopy, and scanning electron microscopy. The larvicidal efficacy was tested against all larval stages of A. stephensi, C. quinquefasciatus, and A. aegypti and calculated by probit analysis at six different log concentrations at the time points of 24, 48, and 72 hours.
Results: The AuNPs synthesized by A. niger were found to be more effective against the C. quinquefasciatus larvae than the A. stephensi and A. aegypti larvae. All larval instars of C. quinquefasciatus showed 100% mortality after 48 hours of exposure to the AuNPs synthesized by A. niger.
Conclusion: The results suggest that the use of AuNPs synthesized by fungus can be a more rapid and environmentally friendly approach for mosquito control than current approaches. This could potentially lead to a new vector control strategy.
Keywords: nanoparticles, biosynthesis, fungi, larvicide, mosquito-borne disease
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.